In 2003, Scott Rocklage joined 5AM Ventures as a venture partner. By 2004 he had been promoted to become a managing partner in the company. Dr. Scott has more than 30 years of experience in health management.

His strategic leadership responsibilities were instrumental in the approval of the new drug applications (Cubicin, Teslascan, and Omniscan) by the FDA in the United States. He has also made it possible for several drug candidates to enter clinical trials.

Rocklage has served as the CEO and Chairman of Cubist Pharmaceuticals as well as the CEO and President of Nycomed Salutar. He has also held various R&D positions at Catalytica and Salutar.

He was the former board chairman of Novira (later acquired by Johnson and Johnson) and Relypsa (NASDAQ: RLYP). Dr. Scott Rocklage serves as the board chairman of Cidara (NASDAQ: CDTX), Kinestral, and Rennovia. He is also on the boards of Pulmatrix (NASDAQ: PULM) and Epirus (NASDAQ: EPRS).

Dr. Scott was the former executive chairman of Semprus (acquired by Teleflex), Miikana (acquired by EntreMed), and Ilypsa (acquired by Amgen).

He received his Bachelor of Science degree in Chemistry from the University of California, Berkley. His PhD. in Chemistry was obtained from MIT (Michigan Institute of Technology). At MIT he did research using Richard Schrock’s laboratory, the 2005 Nobel Prize winner in Chemistry.

Rocklage is the co-inventor or inventor of more than 100 peer reviewed publications as well as 30 U.S. patents. He is currently based in the Boston, Massachusetts office. Scott is currently on the board of associates at the Whitehead Institute. He also serves as MDS Proteomics Inc.’s director.

Read more: Scott Racklage | Bloomberg and Scott Racklage | Crunchbase